Purinergic P2X7 receptors as therapeutic targets in interstitial cystitis/bladder pain syndrome; key role of ATP signaling in inflammation

Main Article Content

Zhinoos Taidi
Kylie J. Mansfield
Lucy Bates
Hafiz Sana-Ur-Rehman
Lu Liu

Keywords

ATP, bladder pain syndrome, inflammation, interstitial cystitis, purinergic receptors

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic lower urinary tract condition. Patients with IC/BPS suffer from debilitating pain and urinary urgency. The underlying etiology of IC/BPS is unknown and as such current treatments are mostly symptomatic with no real cure. Many theories have been proposed to describe the etiology of IC/BPS, but this review focuses on the role of inflammation. In IC/BPS patients, the permeability of the urothelium barrier is compromised and inflammatory cells infiltrate the bladder wall. There are increased levels of many inflammatory mediators in patients with IC/BPS and symptoms such as pain and urgency that have been associated with the degree of inflammation. Recent evidence has highlighted the role of purinergic receptors, specifically the P2X7 receptor, in the process of inflammation. The results from studies in animals including cyclophosphamide-induced hemorrhagic cystitis strongly support the role of P2X7 receptors in inflammation. Furthermore, the deletion of the P2X7 receptor or antagonism of this receptor significantly reduces inflammatory mediator release from the bladder and improves symptoms. Research results from IC/BPS patients and animal models of IC/BPS strongly support the crucial role of inflammation in the pathophysiology of this painful disease. Purinergic signaling and purinergic receptors, especially the P2X7 receptor, play an undisputed role in inflammation. Purinergic receptor antagonists show positive results in treating different symptoms of IC/BPS.

Metrics

Metrics Loading ...
Abstract 276 | HTML Downloads 24 PDF Downloads 88

References

1. Cox A, Golda N, Nadeau G, Curtis Nickel J, Carr L, Corcos J, et al. CUA guideline: Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Canadian Urological Association Journal. 2016;10(5-6):E136-E55. doi: 10.5489/cuaj.3786. PubMed PMID: PMC5065402.
2. Warren JW, Meyer WA, Greenberg P, Horne L, Diggs C, Tracy JK. Using the International Continence Society's definition of painful bladder syndrome. Urology. 2006;67(6):1138-43. doi: 10.1016/j.urology.2006.01.086. PubMed PMID: 16765165.
3. van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. European urology. 2008;53(1):60-7. Epub 2007/09/29. doi: 10.1016/j.eururo.2007.09.019. PubMed PMID: 17900797.
4. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. American journal of obstetrics and gynecology. 2002;187(1):116-26. Epub 2002/07/13. PubMed PMID: 12114899.
5. Horn T, Holm NR, Hald T. Interstitial cystitis. Ultrastructural observations on detrusor smooth muscle cells. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 1998;106(9):909-16. Epub 1998/11/10. PubMed PMID: 9808418.
6. Bogart LM, Berry SH, Clemens JQ. Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review. J Urol. 2007;177(2):450-6. Epub 2007/01/16. doi: 10.1016/j.juro.2006.09.032. PubMed PMID: 17222607.
7. Foster HE, Jr., Hanno PM, Nickel JC, Payne CK, Mayer RD, Burks DA, et al. Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183(5):1853-8. Epub 2010/03/23. doi: 10.1016/j.juro.2009.12.106. PubMed PMID: 20303115; PubMed Central PMCID: PMCPMC2861998.
8. Colaco M, Evans R. Current guidelines in the management of interstitial cystitis. Translational Andrology and Urology. 2015;4(6):677-83. doi: 10.3978/j.issn.2223-4683.2015.11.03. PubMed PMID: PMC4708542.
9. van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004;172(2):533-6. Epub 2004/07/13. doi: 10.1097/01.ju.0000132388.54703.4d. PubMed PMID: 15247722.
10. Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185(6):2162-70. Epub 2011/04/19. doi: 10.1016/j.juro.2011.03.064. PubMed PMID: 21497847.
11. Sairanen J, Tammela TL, Leppilahti M, Multanen M, Paananen I, Lehtoranta K, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol. 2005;174(6):2235-8. Epub 2005/11/11. doi: 10.1097/01.ju.0000181808.45786.84. PubMed PMID: 16280777.
12. Forrest JB, Payne CK, Erickson DR. Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers. J Urol. 2012;188(4):1186-91. Epub 2012/08/21. doi: 10.1016/j.juro.2012.06.023. PubMed PMID: 22901569.
13. Theoharides TC, Sant GR. Hydroxyzine therapy for interstitial cystitis. Urology. 1997;49(5A Suppl):108-10. Epub 1997/05/01. PubMed PMID: 9146011.
14. Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol. 1988;140(1):36-9. Epub 1988/07/01. PubMed PMID: 3288775.
15. Parsons CL, Housley T, Schmidt JD, Lebow D. Treatment of interstitial cystitis with intravesical heparin. British journal of urology. 1994;73(5):504-7. Epub 1994/05/01. PubMed PMID: 8012771.
16. Parsons CL, Zupkas P, Proctor J, Koziol J, Franklin A, Giesing D, et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. The journal of sexual medicine. 2012;9(1):207-12. Epub 2011/11/16. doi: 10.1111/j.1743-6109.2011.02542.x. PubMed PMID: 22082303.
17. Stav K, Beberashvili I, Lindner A, Leibovici D. Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with interstitial cystitis. Urology. 2012;80(1):61-5. Epub 2012/07/04. doi: 10.1016/j.urology.2012.03.030. PubMed PMID: 22748865.
18. Kuo HC. Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. Pain physician. 2013;16(1):E15-23. Epub 2013/01/24. PubMed PMID: 23340540.
19. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. European urology. 2006;49(4):704-9. Epub 2006/01/19. doi: 10.1016/j.eururo.2005.12.002. PubMed PMID: 16417964.
20. Giannantoni A, Mearini E, Del Zingaro M, Proietti S, Porena M. Two-year efficacy and safety of botulinum a toxin intravesical injections in patients affected by refractory painful bladder syndrome. Current drug delivery. 2010;7(1):1-4. Epub 2009/10/30. PubMed PMID: 19863481.
21. Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. European urology. 2010;58(3):360-5. Epub 2010/03/17. doi: 10.1016/j.eururo.2010.02.031. PubMed PMID: 20227820.
22. Barua JM, Arance I, Angulo JC, Riedl CR. A systematic review and meta-analysis on the efficacy of intravesical therapy for bladder pain syndrome/interstitial cystitis. International urogynecology journal. 2016;27:1137-47. doi: 10.1007/s00192-015-2890-7. PubMed PMID: PMC4947101.
23. Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003;170(3):810-5. Epub 2003/08/13. doi: 10.1097/01.ju.0000083020.06212.3d. PubMed PMID: 12913705.
24. Bade JJ, Laseur M, Nieuwenburg A, van der Weele LT, Mensink HJ. A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis. British journal of urology. 1997;79(2):168-71. Epub 1997/02/01. PubMed PMID: 9052464.
25. Sairanen J, Leppilahti M, Tammela TL, Paananen I, Aaltomaa S, Taari K, et al. Evaluation of health-related quality of life in patients with painful bladder syndrome/interstitial cystitis and the impact of four treatments on it. Scandinavian journal of urology and nephrology. 2009;43(3):212-9. Epub 2009/01/13. doi: 10.1080/00365590802671031. PubMed PMID: 19137459.
26. Tutolo M, Ammirati E, Castagna G, Klockaerts K, Plancke H, Ost D, et al. A prospective randomized controlled multicentre trial comparing intravesical DMSO and chondroitin sulphate 2% for painful bladder syndrome/interstitial cystitis. International braz j urol : official journal of the Brazilian Society of Urology. 2017;43(1):134-41. Epub 2017/01/27. doi: 10.1590/s1677-5538.Ibju.2016.0302. PubMed PMID: 28124536; PubMed Central PMCID: PMCPMC5293394.
27. Johansson SL, Fall M. Clinical features and spectrum of light microscopic changes in interstitial cystitis. J Urol. 1990;143(6):1118-24. Epub 1990/06/01. PubMed PMID: 2342171.
28. Logadottir Y, Fall M, Kabjorn-Gustafsson C, Peeker R. Clinical characteristics differ considerably between phenotypes of bladder pain syndrome/interstitial cystitis. Scandinavian journal of urology and nephrology. 2012;46(5):365-70. Epub 2012/05/23. doi: 10.3109/00365599.2012.689008. PubMed PMID: 22607036.
29. Tomoe H. In what type of interstitial cystitis/bladder pain syndrome is DMSO intravesical instillation therapy effective? Translational Andrology and Urology. 2015;4(6):600-4. doi: 10.3978/j.issn.2223-4683.2015.09.01. PubMed PMID: PMC4708538.
30. Lee JE, Yi BH, Lee HK, Lee MH, Kim YH. Correlation of cystoscopically confirmed periureterally located hunner lesion with vesicoureteral reflux: preliminary study in patients with interstitial cystitis. AJR American journal of roentgenology. 2015;204(4):W457-60. Epub 2015/03/21. doi: 10.2214/ajr.14.13108. PubMed PMID: 25794095.
31. Grover S, Srivastava A, Lee R, Tewari AK, Te AE. Role of inflammation in bladder function and interstitial cystitis. Therapeutic Advances in Urology. 2011;3(1):19-33. doi: 10.1177/1756287211398255. PubMed PMID: PMC3126088.
32. Liu HT, Jiang YH, Kuo HC. Alteration of Urothelial Inflammation, Apoptosis, and Junction Protein in Patients with Various Bladder Conditions and Storage Bladder Symptoms Suggest Common Pathway Involved in Underlying Pathophysiology. Lower urinary tract symptoms. 2015;7(2):102-7. Epub 2015/12/15. doi: 10.1111/luts.12062. PubMed PMID: 26663690.
33. Eldrup J, Thorup J, Nielsen SL, Hald T, Hainau B. Permeability and ultrastructure of human bladder epithelium. British journal of urology. 1983;55(5):488-92. Epub 1983/10/01. PubMed PMID: 6626894.
34. Said JW, Van de Velde R, Gillespie L. Immunopathology of interstitial cystitis. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 1989;2(6):593-602. Epub 1989/11/01. PubMed PMID: 2685811.
35. Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol. 1991;145(4):732-5. Epub 1991/04/01. PubMed PMID: 2005689.
36. Liu BL, Yang F, Zhan HL, Feng ZY, Zhang ZG, Li WB, et al. Increased severity of inflammation correlates with elevated expression of TRPV1 nerve fibers and nerve growth factor on interstitial cystitis/bladder pain syndrome. Urologia internationalis. 2014;92(2):202-8. Epub 2014/01/25. doi: 10.1159/000355175. PubMed PMID: 24458144.
37. Pang X, Cotreau-Bibbo MM, Sant GR, Theoharides TC. Bladder mast cell expression of high affinity oestrogen receptors in patients with interstitial cystitis. British journal of urology. 1995;75(2):154-61. Epub 1995/02/01. PubMed PMID: 7850318.
38. Pang X, Marchand J, Sant GR, Kream RM, Theoharides TC. Increased number of substance P positive nerve fibres in interstitial cystitis. British journal of urology. 1995;75(6):744-50. Epub 1995/06/01. PubMed PMID: 7542136.
39. Yamada T, Murayama T, Mita H, Akiyama K. Subtypes of bladder mast cells in interstitial cystitis. International journal of urology : official journal of the Japanese Urological Association. 2000;7(8):292-7. Epub 2000/09/08. PubMed PMID: 10976817.
40. Slobodov G, Feloney M, Gran C, Kyker KD, Hurst RE, Culkin DJ. Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis. J Urol. 2004;171(4):1554-8. Epub 2004/03/17. doi: 10.1097/01.ju.0000118938.09119.a5. PubMed PMID: 15017219.
41. Graham E, Chai TC. Dysfunction of bladder urothelium and bladder urothelial cells in interstitial cystitis. Current urology reports. 2006;7(6):440-6. Epub 2006/10/21. PubMed PMID: 17052438.
42. Montalbetti N, Rued AC, Clayton DR, Ruiz WG, Bastacky SI, Prakasam HS, et al. Increased urothelial paracellular transport promotes cystitis. American journal of physiology Renal physiology. 2015;309(12):F1070-81. Epub 2015/10/02. doi: 10.1152/ajprenal.00200.2015. PubMed PMID: 26423859; PubMed Central PMCID: PMCPMC4683306.
43. Sasisekharan R, Raman R, Prabhakar V. Glycomics approach to structure-function relationships of glycosaminoglycans. Annual review of biomedical engineering. 2006;8:181-231. Epub 2006/07/13. doi: 10.1146/annurev.bioeng.8.061505.095745. PubMed PMID: 16834555.
44. Hurst RE, Roy JB, Min KW, Veltri RW, Marley G, Patton K, et al. A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology. 1996;48(5):817-21. Epub 1996/11/01. doi: 10.1016/s0090-4295(96)00322-6. PubMed PMID: 8911536.
45. Hurst RE. A Deficit of Proteoglycans on the Bladder Uroepithelium in Interstitial Cystitis. European Urology Supplements. 2(4):10-3. doi: 10.1016/S1569-9056(03)00033-2.
46. Lavelle JP, Negrete HO, Poland PA, Kinlough CL, Meyers SD, Hughey RP, et al. Low permeabilities of MDCK cell monolayers: a model barrier epithelium. The American journal of physiology. 1997;273(1 Pt 2):F67-75. Epub 1997/07/01. doi: 10.1152/ajprenal.1997.273.1.F67. PubMed PMID: 9249593.
47. Huygens A, Crnolatac I, Maes J, Van Cleynenbreugel B, Van Poppel H, Roskams T, et al. Influence of the glycosaminoglycan layer on the permeation of hypericin in rat bladders in vivo. BJU international. 2007;100(5):1176-81. Epub 2007/09/18. doi: 10.1111/j.1464-410X.2007.07167.x. PubMed PMID: 17868424.
48. Lewis SA. Everything you wanted to know about the bladder epithelium but were afraid to ask. American journal of physiology Renal physiology. 2000;278(6):F867-74. Epub 2000/06/03. doi: 10.1152/ajprenal.2000.278.6.F867. PubMed PMID: 10836974.
49. Lewis SA, Berg JR, Kleine TJ. Modulation of epithelial permeability by extracellular macromolecules. Physiological reviews. 1995;75(3):561-89. Epub 1995/07/01. doi: 10.1152/physrev.1995.75.3.561. PubMed PMID: 7624394.
50. Cvach K, Rosamilia A. Review of intravesical therapies for bladder pain syndrome/interstitial cystitis. Translational Andrology and Urology. 2015;4(6):629-37. doi: 10.3978/j.issn.2223-4683.2015.10.07. PubMed PMID: PMC4708535.
51. Katnik-Prastowska I, Lis J, Matejuk A. Glycosylation of uroplakins. Implications for bladder physiopathology. Glycoconjugate journal. 2014;31(9):623-36. Epub 2014/11/15. doi: 10.1007/s10719-014-9564-4. PubMed PMID: 25394961; PubMed Central PMCID: PMCPMC4245495.
52. Aldenborg F, Fall M, Enerbäck L. Proliferation and transepithelial migration of mucosal mast cells in interstitial cystitis. Immunology. 1986;58(3):411-6. PubMed PMID: PMC1453481.
53. Logadottir Y, Delbro D, Fall M, Gjertsson I, Jirholt P, Lindholm C, et al. Cytokine expression in patients with bladder pain syndrome/interstitial cystitis ESSIC type 3C. J Urol. 2014;192(5):1564-8. Epub 2014/05/13. doi: 10.1016/j.juro.2014.04.099. PubMed PMID: 24813342.
54. Dodd LG, Tello J. Cytologic examination of urine from patients with interstitial cystitis. Acta cytologica. 1998;42(4):923-7. Epub 1998/07/31. PubMed PMID: 9684578.
55. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nature reviews Immunology. 2013;13(3):159-75. Epub 2013/02/26. doi: 10.1038/nri3399. PubMed PMID: 23435331.
56. Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nature reviews Drug discovery. 2013;12(2):117-29. Epub 2013/01/22. doi: 10.1038/nrd3838. PubMed PMID: 23334207; PubMed Central PMCID: PMCPMC3822762.
57. Fall M, Johansson SL, Aldenborg F. Chronic interstitial cystitis: a heterogeneous syndrome. J Urol. 1987;137(1):35-8. Epub 1987/01/01. PubMed PMID: 3795363.
58. Zhong CJ, Wang K, Zhang L, Yang CQ, Zhang K, Zhou SP, et al. Mast cell activation is involved in stress-induced epithelial barrier dysfunction in the esophagus. Journal of digestive diseases. 2015;16(4):186-96. Epub 2015/01/08. doi: 10.1111/1751-2980.12226. PubMed PMID: 25565566.
59. Peeker R, Enerback L, Fall M, Aldenborg F. Recruitment, distribution and phenotypes of mast cells in interstitial cystitis. J Urol. 2000;163(3):1009-15. Epub 2000/02/25. PubMed PMID: 10688040.
60. Hofmeister MA, He F, Ratliff TL, Mahoney T, Becich MJ. Mast cells and nerve fibers in interstitial cystitis (IC): an algorithm for histologic diagnosis via quantitative image analysis and morphometry (QIAM). Urology. 1997;49(5A Suppl):41-7. Epub 1997/05/01. PubMed PMID: 9146000.
61. Sant GR, Theoharides TC. The role of the mast cell in interstitial cystitis. The Urologic clinics of North America. 1994;21(1):41-53. Epub 1994/02/01. PubMed PMID: 8284844.
62. Holm-Bentzen M, Sondergaard I, Hald T. Urinary excretion of a metabolite of histamine (1,4-methyl-imidazole-acetic-acid) in painful bladder disease. British journal of urology. 1987;59(3):230-3. Epub 1987/03/01. PubMed PMID: 3567484.
63. Lamale LM, Lutgendorf SK, Zimmerman MB, Kreder KJ. Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis. Urology. 2006;68(4):702-6. Epub 2006/10/31. doi: 10.1016/j.urology.2006.04.033. PubMed PMID: 17070335.
64. Koskela LR, Thiel T, Ehren I, De Verdier PJ, Wiklund NP. Localization and expression of inducible nitric oxide synthase in biopsies from patients with interstitial cystitis. J Urol. 2008;180(2):737-41. Epub 2008/06/17. doi: 10.1016/j.juro.2008.03.184. PubMed PMID: 18554637.
65. Sharma JN, Al-Omran A, Parvathy SS. Role of nitric oxide in inflammatory diseases. Inflammopharmacology. 2007;15(6):252-9. Epub 2008/02/01. doi: 10.1007/s10787-007-0013-x. PubMed PMID: 18236016.
66. Offiah I, Didangelos A, Dawes J, Cartwright R, Khullar V, Bradbury EJ, et al. The Expression of Inflammatory Mediators in Bladder Pain Syndrome. European urology. 2016;70(2):283-90. Epub 2016/03/12. doi: 10.1016/j.eururo.2016.02.058. PubMed PMID: 26965559; PubMed Central PMCID: PMCPMC4926725.
67. Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerging Microbes &Amp; Infections. 2013;2:e60. doi: 10.1038/emi.2013.58.
68. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity. 2009;30(1):108-19. Epub 2009/01/16. doi: 10.1016/j.immuni.2008.11.009. PubMed PMID: 19144317.
69. Tanaka T, Narazaki M, Kishimoto T. IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harbor Perspectives in Biology. 2014;6(10):a016295. doi: 10.1101/cshperspect.a016295. PubMed PMID: PMC4176007.
70. Schrepf A, O'Donnell M, Luo Y, Bradley CS, Kreder K, Lutgendorf S. Inflammation and inflammatory control in interstitial cystitis/bladder pain syndrome: Associations with painful symptoms. Pain. 2014;155(9):1755-61. Epub 2014/06/08. doi: 10.1016/j.pain.2014.05.029. PubMed PMID: 24907404; PubMed Central PMCID: PMCPMC4166494.
71. Jiang YH, Peng CH, Liu HT, Kuo HC. Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome. PLoS One. 2013;8(10):e76779. Epub 2013/10/23. doi: 10.1371/journal.pone.0076779. PubMed PMID: 24146927; PubMed Central PMCID: PMCPMC3798602.
72. Sakthivel SK, Singh UP, Singh S, Taub DD, Novakovic KR, Lillard JW, Jr. CXCL10 blockade protects mice from cyclophosphamide-induced cystitis. Journal of immune based therapies and vaccines. 2008;6:6. Epub 2008/10/30. doi: 10.1186/1476-8518-6-6. PubMed PMID: 18957084; PubMed Central PMCID: PMCPMC2583981.
73. Martins JP, Silva RB, Coutinho-Silva R, Takiya CM, Battastini AM, Morrone FB, et al. The role of P2X7 purinergic receptors in inflammatory and nociceptive changes accompanying cyclophosphamide-induced haemorrhagic cystitis in mice. British journal of pharmacology. 2012;165(1):183-96. Epub 2011/06/17. doi: 10.1111/j.1476-5381.2011.01535.x. PubMed PMID: 21675966; PubMed Central PMCID: PMCPMC3252976.
74. Christmas TJ, Rode J, Chapple CR, Milroy EJ, Turner-Warwick RT. Nerve fibre proliferation in interstitial cystitis. Virchows Archiv A, Pathological anatomy and histopathology. 1990;416(5):447-51. Epub 1990/01/01. PubMed PMID: 2107633.
75. Lundeberg T, Liedberg H, Nordling L, Theodorsson E, Owzarski A, Ekman P. Interstitial cystitis: correlation with nerve fibres, mast cells and histamine. British journal of urology. 1993;71(4):427-9. Epub 1993/04/01. PubMed PMID: 8499987.
76. Kim SW, Im YJ, Choi HC, Kang HJ, Kim JY, Kim JH. Urinary nerve growth factor correlates with the severity of urgency and pain. International urogynecology journal. 2014;25(11):1561-7. Epub 2014/05/29. doi: 10.1007/s00192-014-2424-8. PubMed PMID: 24866276.
77. Yaraee R, Ebtekar M, Ahmadiani A, Sabahi F. Neuropeptides (SP and CGRP) augment pro-inflammatory cytokine production in HSV-infected macrophages. Int Immunopharmacol. 2003;3(13-14):1883-7. doi: 10.1016/s1567-5769(03)00201-7. PubMed PMID: 14636837.
78. Azzolina A, Bongiovanni A, Lampiasi N. Substance P induces TNF-alpha and IL-6 production through NF kappa B in peritoneal mast cells. Biochimica et biophysica acta. 2003;1643(1-3):75-83. Epub 2003/12/05. PubMed PMID: 14654230.
79. Ang SF, Moochhala SM, MacAry PA, Bhatia M. Hydrogen sulfide and neurogenic inflammation in polymicrobial sepsis: involvement of substance P and ERK-NF-kappaB signaling. PLoS One. 2011;6(9):e24535. Epub 2011/09/21. doi: 10.1371/journal.pone.0024535. PubMed PMID: 21931742; PubMed Central PMCID: PMCPMC3171449.
80. Bhatia M, Zhi L, Zhang H, Ng S-W, Moore PK. Role of substance P in hydrogen sulfide-induced pulmonary inflammation in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology. 2006;291(5):L896.
81. Hegde A, Tamizhselvi R, Manikandan J, Melendez AJ, Moochhala SM, Bhatia M. Substance P in Polymicrobial Sepsis: Molecular Fingerprint of Lung Injury in Preprotachykinin-A(−/−) Mice. Molecular Medicine. 2010;16(5-6):188-98. doi: 10.2119/molmed.2009.00166. PubMed PMID: PMC2864813.
82. Sio SWS, Ang SF, Lu J, Moochhala S, Bhatia M. Substance P Upregulates Cyclooxygenase-2 and Prostaglandin E Metabolite by Activating ERK1/2 and NF-κB in a Mouse Model of Burn-Induced Remote Acute Lung Injury. The Journal of Immunology. 2010;185(10):6265-76. doi: 10.4049/jimmunol.1001739.
83. Sio SW, Puthia MK, Lu J, Moochhala S, Bhatia M. The neuropeptide substance P is a critical mediator of burn-induced acute lung injury. Journal of immunology (Baltimore, Md : 1950). 2008;180(12):8333-41. Epub 2008/06/05. PubMed PMID: 18523300.
84. Sipos G, Sipos P, Altdorfer K, Pongor E, Feher E. Correlation and immunolocalization of substance P nerve fibers and activated immune cells in human chronic gastritis. Anatomical record (Hoboken, NJ : 2007). 2008;291(9):1140-8. Epub 2008/08/30. doi: 10.1002/ar.20737. PubMed PMID: 18727057.
85. Burnstock G. Purinergic nerves. Pharmacological reviews. 1972;24(3):509-81. Epub 1972/09/01. PubMed PMID: 4404211.
86. Kitta T, Chancellor MB, de Groat WC, Kuno S, Nonomura K, Yoshimura N. Roles of adenosine A1 and A2A receptors in the control of micturition in rats. Neurourology and urodynamics. 2014;33(8):1259-65. Epub 2013/09/10. doi: 10.1002/nau.22487. PubMed PMID: 24014261.
87. Silva I, Costa AF, Moreira S, Ferreirinha F, Magalhaes-Cardoso MT, Calejo I, et al. Inhibition of cholinergic neurotransmission by beta3-adrenoceptors depends on adenosine release and A1-receptor activation in human and rat urinary bladders. American journal of physiology Renal physiology. 2017;313(2):F388-f403. Epub 2017/04/28. doi: 10.1152/ajprenal.00392.2016. PubMed PMID: 28446460.
88. Pakzad M, Ikeda Y, McCarthy C, Kitney DG, Jabr RI, Fry CH. Contractile effects and receptor analysis of adenosine-receptors in human detrusor muscle from stable and neuropathic bladders. Naunyn-Schmiedeberg's archives of pharmacology. 2016;389(8):921-9. Epub 2016/05/18. doi: 10.1007/s00210-016-1255-1. PubMed PMID: 27185496; PubMed Central PMCID: PMCPMC4939168.
89. Searl TJ, Dynda DI, Alanee SR, El-Zawahry AM, McVary KT, Silinsky EM. A1 Adenosine Receptor-Mediated Inhibition of Parasympathetic Neuromuscular Transmission in Human and Murine Urinary Bladder. The Journal of pharmacology and experimental therapeutics. 2016;356(1):116-22. Epub 2015/11/05. doi: 10.1124/jpet.115.228882. PubMed PMID: 26534943; PubMed Central PMCID: PMCPMC4702072.
90. Burnstock G. Purine and pyrimidine receptors. Cellular and molecular life sciences : CMLS. 2007;64(12):1471-83. Epub 2007/03/22. doi: 10.1007/s00018-007-6497-0. PubMed PMID: 17375261.
91. Chen X, Gebhart GF. Differential purinergic signaling in bladder sensory neurons of naïve and bladder-inflamed mice. Pain. 2010;148(3):462-72. Epub 2009/12/31. doi: 10.1016/j.pain.2009.12.006. PubMed PMID: 20045252.
92. Lee HY, Bardini M, Burnstock G. Distribution of P2X receptors in the urinary bladder and the ureter of the rat. J Urol. 2000;163(6):2002-7. Epub 2000/05/08. PubMed PMID: 10799247.
93. Vial C, Evans RJ. P2X receptor expression in mouse urinary bladder and the requirement of P2X(1) receptors for functional P2X receptor responses in the mouse urinary bladder smooth muscle. British journal of pharmacology. 2000;131(7):1489-95. doi: 10.1038/sj.bjp.0703720. PubMed PMID: PMC1572476.
94. Menzies J, Paul A, Kennedy C. P2X7 subunit-like immunoreactivity in the nucleus of visceral smooth muscle cells of the guinea pig. Autonomic neuroscience : basic & clinical. 2003;106(2):103-9. Epub 2003/07/25. doi: 10.1016/s1566-0702(03)00078-x. PubMed PMID: 12878079.
95. Svennersten K, Hallen-Grufman K, de Verdier PJ, Wiklund NP, Poljakovic M. Localization of P2X receptor subtypes 2, 3 and 7 in human urinary bladder. BMC urology. 2015;15:81. Epub 2015/08/09. doi: 10.1186/s12894-015-0075-9. PubMed PMID: 26253104; PubMed Central PMCID: PMCPMC4529706.
96. Shabir S, Cross W, Kirkwood LA, Pearson JF, Appleby PA, Walker D, et al. Functional expression of purinergic P2 receptors and transient receptor potential channels by the human urothelium. American journal of physiology Renal physiology. 2013;305(3):F396-F406. Epub 2013/05/29. doi: 10.1152/ajprenal.00127.2013. PubMed PMID: 23720349.
97. Tempest HV, Dixon AK, Turner WH, Elneil S, Sellers LA, Ferguson DR. P2X and P2X receptor expression in human bladder urothelium and changes in interstitial cystitis. BJU international. 2004;93(9):1344-8. Epub 2004/06/08. doi: 10.1111/j.1464-410X.2004.04858.x. PubMed PMID: 15180635.
98. Chua WC, Liu L, Mansfield KJ, Vaux KJ, Moore KH, Millard RJ, et al. Age-related changes of P2X(1) receptor mRNA in the bladder detrusor from men with and without bladder outlet obstruction. Experimental gerontology. 2007;42(7):686-92. Epub 2007/04/03. doi: 10.1016/j.exger.2007.02.003. PubMed PMID: 17399929.
99. Vlaskovska M, Kasakov L, Rong W, Bodin P, Bardini M, Cockayne DA, et al. P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2001;21(15):5670-7. Epub 2001/07/24. PubMed PMID: 11466438.
100. Birder LA, Ruan HZ, Chopra B, Xiang Z, Barrick S, Buffington CA, et al. Alterations in P2X and P2Y purinergic receptor expression in urinary bladder from normal cats and cats with interstitial cystitis. American journal of physiology Renal physiology. 2004;287(5):F1084-91. Epub 2004/07/15. doi: 10.1152/ajprenal.00118.2004. PubMed PMID: 15251862.
101. Chopra B, Gever J, Barrick SR, Hanna-Mitchell AT, Beckel JM, Ford APDW, et al. Expression and function of rat urothelial P2Y receptors. American journal of physiology Renal physiology. 2008;294(4):F821-F9. Epub 2008/01/23. doi: 10.1152/ajprenal.00321.2006. PubMed PMID: 18216148.
102. Carneiro I, Timoteo MA, Silva I, Vieira C, Baldaia C, Ferreirinha F, et al. Activation of P2Y6 receptors increases the voiding frequency in anaesthetized rats by releasing ATP from the bladder urothelium. British journal of pharmacology. 2014;171(14):3404-19. Epub 2014/04/05. doi: 10.1111/bph.12711. PubMed PMID: 24697602; PubMed Central PMCID: PMCPMC4105929.
103. Timoteo MA, Carneiro I, Silva I, Noronha-Matos JB, Ferreirinha F, Silva-Ramos M, et al. ATP released via pannexin-1 hemichannels mediates bladder overactivity triggered by urothelial P2Y6 receptors. Biochem Pharmacol. 2014;87(2):371-9. Epub 2013/11/26. doi: 10.1016/j.bcp.2013.11.007. PubMed PMID: 24269631.
104. Sui GP, Wu C, Fry CH. Characterization of the purinergic receptor subtype on guinea-pig suburothelial myofibroblasts. BJU international. 2006;97(6):1327-31. Epub 2006/05/12. doi: 10.1111/j.1464-410X.2006.06200.x. PubMed PMID: 16686733.
105. Collins VM, Daly DM, Liaskos M, McKay NG, Sellers D, Chapple C, et al. OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium. BJU international. 2013;112(7):1018-26. Epub 2013/08/14. doi: 10.1111/bju.12266. PubMed PMID: 23937318.
106. Cockayne DA, Hamilton SG, Zhu QM, Dunn PM, Zhong Y, Novakovic S, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 2000;407(6807):1011-5. Epub 2000/11/09. doi: 10.1038/35039519. PubMed PMID: 11069181.
107. Sun Y, Keay S, De Deyne PG, Chai TC. Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis. J Urol. 2001;166(5):1951-6. Epub 2001/10/05. PubMed PMID: 11586266.
108. Sun Y, Chai TC. Augmented extracellular ATP signaling in bladder urothelial cells from patients with interstitial cystitis. American journal of physiology Cell physiology. 2006;290(1):C27-34. Epub 2005/08/19. doi: 10.1152/ajpcell.00552.2004. PubMed PMID: 16107499.
109. Ferguson DR, Kennedy I, Burton TJ. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes--a possible sensory mechanism? The Journal of physiology. 1997;505 ( Pt 2):503-11. Epub 1998/01/10. PubMed PMID: 9423189; PubMed Central PMCID: PMCPMC1160080.
110. Sadananda P, Shang F, Liu L, Mansfield KJ, Burcher E. Release of ATP from rat urinary bladder mucosa: role of acid, vanilloids and stretch. British journal of pharmacology. 2009;158(7):1655-62. Epub 2009/10/29. doi: 10.1111/j.1476-5381.2009.00431.x. PubMed PMID: 19860742; PubMed Central PMCID: PMCPMC2801206.
111. Birder LA, Barrick SR, Roppolo JR, Kanai AJ, de Groat WC, Kiss S, et al. Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from bladder urothelium. American journal of physiology Renal physiology. 2003;285(3):F423-9. Epub 2003/05/22. doi: 10.1152/ajprenal.00056.2003. PubMed PMID: 12759226.
112. Lazarowski ER. Vesicular and conductive mechanisms of nucleotide release. Purinergic signalling. 2012;8(3):359-73. Epub 2012/04/25. doi: 10.1007/s11302-012-9304-9. PubMed PMID: 22528679; PubMed Central PMCID: PMCPMC3360093.
113. Lohman AW, Billaud M, Isakson BE. Mechanisms of ATP release and signalling in the blood vessel wall. Cardiovascular research. 2012;95(3):269-80. Epub 2012/06/09. doi: 10.1093/cvr/cvs187. PubMed PMID: 22678409; PubMed Central PMCID: PMCPMC3400358.
114. Burnstock G. Historical review: ATP as a neurotransmitter. Trends in pharmacological sciences. 2006;27(3):166-76. Epub 2006/02/21. doi: 10.1016/j.tips.2006.01.005. PubMed PMID: 16487603.
115. Ho T, Jobling AI, Greferath U, Chuang T, Ramesh A, Fletcher EL, et al. Vesicular expression and release of ATP from dopaminergic neurons of the mouse retina and midbrain. Front Cell Neurosci. 2015;9:389. Epub 2015/10/27. doi: 10.3389/fncel.2015.00389. PubMed PMID: 26500494; PubMed Central PMCID: PMCPMC4593860.
116. Sana-Ur-Rehman H, Markus I, Moore KH, Mansfield KJ, Liu L. Expression and localization of pannexin-1 and CALHM1 in porcine bladder and their involvement in modulating ATP release. American journal of physiology Regulatory, integrative and comparative physiology. 2017:ajpregu.00039.2016. Epub 2017/03/04. doi: 10.1152/ajpregu.00039.2016. PubMed PMID: 28254749.
117. Locovei S, Scemes E, Qiu F, Spray DC, Dahl G. Pannexin1 is part of the pore forming unit of the P2X(7) receptor death complex. FEBS letters. 2007;581(3):483-8. Epub 2007/01/24. doi: 10.1016/j.febslet.2006.12.056. PubMed PMID: 17240370; PubMed Central PMCID: PMCPMC1868681.
118. Negoro H, Urban-Maldonado M, Liou LS, Spray DC, Thi MM, Suadicani SO. Pannexin 1 channels play essential roles in urothelial mechanotransduction and intercellular signaling. PLoS One. 2014;9(8):e106269. Epub 2014/08/30. doi: 10.1371/journal.pone.0106269. PubMed PMID: 25170954; PubMed Central PMCID: PMCPMC4149561.
119. Sui G, Fry CH, Montgomery B, Roberts M, Wu R, Wu C. Purinergic and muscarinic modulation of ATP release from the urothelium and its paracrine actions. American journal of physiology Renal physiology. 2014;306(3):F286-98. Epub 2013/11/29. doi: 10.1152/ajprenal.00291.2013. PubMed PMID: 24285497; PubMed Central PMCID: PMCPMC3920053.
120. Mansfield KJ, Hughes JR. P2Y Receptor Modulation of ATP Release in the Urothelium. BioMed research international. 2014;2014:830374. doi: 10.1155/2014/830374. PubMed PMID: PMC4009150.
121. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacological reviews. 1998;50(3):413-92. Epub 1998/10/02. PubMed PMID: 9755289.
122. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochimica et biophysica acta. 2008;1783(5):673-94. Epub 2008/02/28. doi: 10.1016/j.bbamcr.2008.01.024. PubMed PMID: 18302942.
123. McMurray G, Dass N, Brading AF. Purinoceptor subtypes mediating contraction and relaxation of marmoset urinary bladder smooth muscle. British journal of pharmacology. 1998;123(8):1579-86. Epub 1998/05/30. doi: 10.1038/sj.bjp.0701774. PubMed PMID: 9605564; PubMed Central PMCID: PMCPMC1565329.
124. Fry CH, Young JS, Jabr RI, McCarthy C, Ikeda Y, Kanai AJ. Modulation of spontaneous activity in the overactive bladder: the role of P2Y agonists. American journal of physiology Renal physiology. 2012;302(11):F1447-54. Epub 2012/02/24. doi: 10.1152/ajprenal.00436.2011. PubMed PMID: 22357922; PubMed Central PMCID: PMCPMC3378171.
125. Birder L, Andersson KE. Urothelial signaling. Physiological reviews. 2013;93(2):653-80. Epub 2013/04/17. doi: 10.1152/physrev.00030.2012. PubMed PMID: 23589830; PubMed Central PMCID: PMCPMC3768101.
126. Rong W, Spyer KM, Burnstock G. Activation and sensitisation of low and high threshold afferent fibres mediated by P2X receptors in the mouse urinary bladder. The Journal of physiology. 2002;541(Pt 2):591-600. Epub 2002/06/04. PubMed PMID: 12042363; PubMed Central PMCID: PMCPMC2290323.
127. Zhong Y, Banning AS, Cockayne DA, Ford AP, Burnstock G, McMahon SB. Bladder and cutaneous sensory neurons of the rat express different functional P2X receptors. Neuroscience. 2003;120(3):667-75. Epub 2003/08/05. PubMed PMID: 12895508.
128. Kumar V, Chapple CR, Surprenant AM, Chess-Williams R. Enhanced adenosine triphosphate release from the urothelium of patients with painful bladder syndrome: a possible pathophysiological explanation. J Urol. 2007;178(4 Pt 1):1533-6. Epub 2007/08/21. doi: 10.1016/j.juro.2007.05.116. PubMed PMID: 17707056.
129. Smith CP, Vemulakonda VM, Kiss S, Boone TB, Somogyi GT. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A. Neurochemistry international. 2005;47(4):291-7. Epub 2005/06/23. doi: 10.1016/j.neuint.2005.04.021. PubMed PMID: 15970360.
130. Montalbetti N, Rued AC, Taiclet SN, Birder LA, Kullmann FA, Carattino MD. Urothelial Tight Junction Barrier Dysfunction Sensitizes Bladder Afferents. eNeuro. 2017;4(3). Epub 2017/06/01. doi: 10.1523/eneuro.0381-16.2017. PubMed PMID: 28560313; PubMed Central PMCID: PMCPMC5442440.
131. Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology. 2007;70(3):463-8. Epub 2007/10/02. doi: 10.1016/j.urology.2007.04.038. PubMed PMID: 17905097.
132. Chiu B, Tai H-C, Chung S-D, Birder LA. Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis. Toxins. 2016;8(7):201. doi: 10.3390/toxins8070201. PubMed PMID: PMC4963834.
133. Cockayne DA, Dunn PM, Zhong Y, Rong W, Hamilton SG, Knight GE, et al. P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP. The Journal of physiology. 2005;567(Pt 2):621-39. Epub 2005/06/18. doi: 10.1113/jphysiol.2005.088435. PubMed PMID: 15961431; PubMed Central PMCID: PMCPmc1474198.
134. Ford AP, Undem BJ. The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Front Cell Neurosci. 2013;7:267. Epub 2014/01/07. doi: 10.3389/fncel.2013.00267. PubMed PMID: 24391544; PubMed Central PMCID: PMCPMC3867694.
135. Ito K, Iwami A, Katsura H, Ikeda M. Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. Naunyn-Schmiedeberg's archives of pharmacology. 2008;377(4-6):483-90. Epub 2007/10/06. doi: 10.1007/s00210-007-0197-z. PubMed PMID: 17917716.
136. Lu SH, Groat WC, Lin AT, Chen KK, Chang LS. Evaluation of purinergic mechanism for the treatment of voiding dysfunction: a study in conscious spinal cord-injured rats. Journal of the Chinese Medical Association : JCMA. 2007;70(10):439-44. Epub 2007/10/27. PubMed PMID: 17962144; PubMed Central PMCID: PMCPmc3119078.
137. De Marchi E, Orioli E, Dal Ben D, Adinolfi E. Chapter Two - P2X7 Receptor as a Therapeutic Target. In: Rossen D, editor. Advances in Protein Chemistry and Structural Biology. Volume 104: Academic Press; 2016. p. 39-79.
138. Gu BJ, Zhang WY, Bendall LJ, Chessell IP, Buell GN, Wiley JS. Expression of P2X(7) purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional P2X(7) receptors. American journal of physiology Cell physiology. 2000;279(4):C1189-97. Epub 2000/09/26. PubMed PMID: 11003599.
139. Keay S, Seillier-Moiseiwitsch F, Zhang CO, Chai TC, Zhang J. Changes in human bladder epithelial cell gene expression associated with interstitial cystitis or antiproliferative factor treatment. Physiological genomics. 2003;14(2):107-15. Epub 2003/07/09. doi: 10.1152/physiolgenomics.00055.2003. PubMed PMID: 12847144.
140. Tseng LH, Chen I, Wang CN, Lin YH, Lloyd LK, Lee CL. Genome-based expression profiling study of Hunner's ulcer type interstitial cystitis: an array of 40-gene model. International urogynecology journal. 2010;21(8):911-8. Epub 2010/03/06. doi: 10.1007/s00192-010-1129-x. PubMed PMID: 20204322.
141. Gamper M, Viereck V, Geissbuhler V, Eberhard J, Binder J, Moll C, et al. Gene expression profile of bladder tissue of patients with ulcerative interstitial cystitis. BMC genomics. 2009;10:199. Epub 2009/04/30. doi: 10.1186/1471-2164-10-199. PubMed PMID: 19400928; PubMed Central PMCID: PMCPMC2686735.
142. Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Melchiorri L, Baricordi OR, et al. Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. The Journal of Immunology. 1997;159(3):1451-8.
143. Ferrari D, Wesselborg S, Bauer MK, Schulze-Osthoff K. Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoreceptor by selectively targeting NF-kappaB p65. The Journal of cell biology. 1997;139(7):1635-43. Epub 1998/02/07. PubMed PMID: 9412459; PubMed Central PMCID: PMCPMC2132650.
144. Lee BH, Hwang DM, Palaniyar N, Grinstein S, Philpott DJ, Hu J. Activation of P2X(7) receptor by ATP plays an important role in regulating inflammatory responses during acute viral infection. PLoS One. 2012;7(4):e35812. Epub 2012/05/05. doi: 10.1371/journal.pone.0035812. PubMed PMID: 22558229; PubMed Central PMCID: PMCPMC3338466.
145. Munoz A, Yazdi IK, Tang X, Rivera C, Taghipour N, Grossman RG, et al. Localized inhibition of P2X7R at the spinal cord injury site improves neurogenic bladder dysfunction by decreasing urothelial P2X3R expression in rats. Life Sciences. 2017;171:60-7. doi: http://dx.doi.org/10.1016/j.lfs.2016.12.017.
146. Goncalves RG, Gabrich L, Rosario A, Jr., Takiya CM, Ferreira ML, Chiarini LB, et al. The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney international. 2006;70(9):1599-606. Epub 2006/09/14. doi: 10.1038/sj.ki.5001804. PubMed PMID: 16969386.
147. Odobasic D, Kitching AR, Holdsworth SR. Neutrophil-Mediated Regulation of Innate and Adaptive Immunity: The Role of Myeloperoxidase. Journal of immunology research. 2016;2016:2349817. Epub 2016/02/24. doi: 10.1155/2016/2349817. PubMed PMID: 26904693; PubMed Central PMCID: PMCPMC4745373.
148. Dell'Antonio G, Quattrini A, Cin ED, Fulgenzi A, Ferrero ME. Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis and rheumatism. 2002;46(12):3378-85. Epub 2002/12/17. doi: 10.1002/art.10678. PubMed PMID: 12483745.
149. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain. 2005;114(3):386-96. Epub 2005/03/22. doi: 10.1016/j.pain.2005.01.002. PubMed PMID: 15777864.
150. Yan Y, Bai J, Zhou X, Tang J, Jiang C, Tolbert E, et al. P2X7 receptor inhibition protects against ischemic acute kidney injury in mice. American Journal of Physiology - Cell Physiology. 2015;308(6):C463-C72. doi: 10.1152/ajpcell.00245.2014. PubMed PMID: PMC4360025.
151. Wan P, Liu X, Xiong Y, Ren Y, Chen J, Lu N, et al. Extracellular ATP mediates inflammatory responses in colitis via P2 x 7 receptor signaling. Sci Rep. 2016;6:19108. Epub 2016/01/08. doi: 10.1038/srep19108. PubMed PMID: 26739809; PubMed Central PMCID: PMCPMC4703960.